natalizumab
biogen
['#ms ', 'natalizumab']
kalincik study: propensity-matched #progressive #ms patients treated with ahsct or natalizumab. no difference on relapse rates and disability progression. #ectrims2022 
Director, MS Center for Innovations in Care. ?? doctor helping people live well with multiple sclerosis. Podcast host: https://t.co/POevAw4x7s  Tweets ? medical advice